CannPal Animal Therapeutics
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
CannPal Animal Therapeutics Limited (CP1) was a listed animal health Company developing innovative and naturally derived plant based therapeutic products for pets targeting the Endocannabinoid System.
The company had a research focus on cannabinoids, the active pharmaceutical ingredients extracted from the cannabis plant, to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal merged with Auscann Group in 2021.
Contact Details
Lists and Charts
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Collapse All Lists and Charts
Company Activity
| NEW ROLE: Margaret Curtis, Head of Research & Development | 24 Nov 2020 |
| NEWS: Tagged in AusCann to acquire animal business for $18m | 16 Nov 2020 |
| REMUNERATION UPDATE: Kate Adams, Non-Executive Director | 13 Nov 2020 |
| REMUNERATION UPDATE: Geoff Starr, Non-Executive Chair | 13 Nov 2020 |
| REMUNERATION UPDATE: Layton Mills, Founder, Chief Executive, Managing Director | 13 Nov 2020 |
| REMUNERATION UPDATE: Robert Clifford, Non-Executive Director | 13 Nov 2020 |
| NEW ROLE: Geoff Starr, Non-Executive Chair | 03 Nov 2020 |
| NEW ROLE: Robert Clifford, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Kate Adams, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Layton Mills, Founder, Chief Executive, Managing Director | 03 Nov 2020 |
